Cancer Genetics Introduces New Partnership with ICON's Laboratory Services

- July 8th, 2015

Cancer Genetics (NASDAQ:CGIX), a DNA-based diagnostics company, announced a partnership with ICON’s Laboratory Services, which provides global testing services to the pharmaceutical, biotechnology, and medical device industries. Together, they will offer complex, oncology-focused genomic testing , laboratory analysis, sample logistics and project and data management to clients. According to the press release: Oncology testing services … Continued

Cancer Genetics (NASDAQ:CGIX), a DNA-based diagnostics company, announced a partnership with ICON’s Laboratory Services, which provides global testing services to the pharmaceutical, biotechnology, and medical device industries. Together, they will offer complex, oncology-focused genomic testing , laboratory analysis, sample logistics and project and data management to clients.
According to the press release:

Oncology testing services are central to CGI’s business model and are also a core focus area for ICON Laboratory Services. Together, the two companies will leverage their respective expertise to provide key insights to the oncology drug development and clinical trial process: ICON’s expertise in strategic development and in management and analysis of lab data from large-scale clinical programmes, and CGI’s extensive knowledge in applying genomics and other advanced technologies focused on cancer. The partnership is focused on providing a comprehensive, integrated and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV.

James Miskel, Executive Vice President of ICON Laboratory Services, says:

We are looking forward to working with the CGI team and to enhancing our client offering with complementary laboratory service programs. Together, CGI and ICON are uniquely positioned to provide a full range of comprehensive lab solutions for our customers with current and future oncology-focused clinical trials.

Click here to read the entire press release.

Leave a Reply